Maraviroc Amarox (Maraviroc)

Maraviroc is used in the management of HIV‑1 infection that utilizes the CCR5 co‑receptor. It is incorporated into combination antiretroviral regimens for patients with specific viral tropism.

• Treatment‑experienced HIV‑1 infection with CCR5‑tropic virus: provides virologic suppression in patients who have previously received antiretroviral therapy.
• CCR5‑tropic HIV‑1 infection: reduces viral load when used as part of a combination regimen.
• Patients with resistance to other antiretrovirals: offers an alternative mechanism of action targeting viral entry.

• Maraviroc selectively binds to the CCR5 co‑receptor on CD4+ T‑cells, blocking the interaction between the receptor and the HIV‑1 envelope glycoprotein gp120. This prevents CCR5‑tropic HIV‑1 from entering and infecting host cells, thereby inhibiting viral replication and spread within the immune system.

Adverse reactions may occur with Maraviroc therapy. Patients should be informed of both common and serious possibilities.

Common Side Effects

• Headache: mild to moderate intensity.
• Nausea: occasional gastrointestinal upset.
• Diarrhea: loose stools, often transient.
• Fatigue: generalized tiredness.
• Cough: non‑productive respiratory irritation.
• Rash: mild skin erythema.

Serious or Rare Side Effects

• Liver toxicity: elevated transaminases or hepatitis.
• Severe allergic reaction: anaphylaxis, angioedema.
• Depression or suicidal ideation: new or worsening mood changes.
• QT interval prolongation: cardiac conduction abnormalities.
• Stevens‑Johnson syndrome or toxic epidermal necrolysis: severe skin reactions.

Before initiating Maraviroc, clinicians should assess several safety considerations.

• Liver function monitoring: check baseline enzymes and repeat periodically.
• Cardiovascular assessment: evaluate for pre‑existing heart disease or arrhythmias.
• Mental health screening: monitor for depression or suicidal thoughts.
• Hypersensitivity evaluation: avoid in patients with known allergy to Maraviroc.
• Renal impairment caution: adjust dosing if significant kidney dysfunction is present.
• Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Maraviroc may interact with other medicines that affect its metabolism or transport.

Major Interactions (Avoid)

• Strong CYP3A4 inducers (e.g., rifampin, carbamazepine, St. John's wort): markedly reduce Maraviroc exposure.
• Concomitant use with protease inhibitors that are not boosted: may lead to unpredictable levels.

Moderate Interactions (Monitor Closely)

• CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin, itraconazole): increase Maraviroc concentrations.
• Certain antacids containing aluminum or magnesium: may affect absorption; separate dosing by at least 2 hours.
• Statins metabolized by CYP3A4 (e.g., simvastatin, lovastatin): monitor for increased statin exposure and muscle toxicity.